Cover Image
市場調查報告書

生物製藥的原料藥 (API)的全球市場

Analysis of the Global Biologics API Market

出版商 Frost & Sullivan 商品編碼 366642
出版日期 內容資訊 英文 53 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物製藥的原料藥 (API)的全球市場 Analysis of the Global Biologics API Market
出版日期: 2016年07月26日 內容資訊: 英文 53 Pages
簡介

本報告提供生物製藥的原料藥 (API)的市場調查,API概要,產品區分和藥效分類,製造流程,影響市場成長因素,相關的法律制度,收益預測,各地區、藥物類型的收益佔有率,市場及技術的主要趨勢,主要企業各公司的未來轉動的計劃,開發平台趨勢,最佳業務實踐分析等彙整資料。

第1章 摘要整理

第2章 整體市場:概要

  • 市場定義
  • 全球生物製藥用API的市場:概要
  • 全球生物製藥用API:產品區分、藥效分類
  • 抗體、組調換蛋白質:製造流程
  • 疫苗、基因治療:製造流程

第3章 整體市場:市場推進因素與阻礙

  • 市場推進因素
  • 市場抑制因素
  • 法律制度:生物製藥

第4章 整體市場:預測、趨勢

  • 市場工程評估
  • 收益預測
  • 收益預測相關討論
  • 各地區收益佔有率的明細
  • 各類藥物收益佔有率的明細

第5章 整體市場:技術、市場趨勢

  • 全球生物製藥市場趨勢
  • 全球生物製藥技術趨勢
  • 主要生物醫藥品企業、CMO的主要企業的擴張
  • 主要生物醫藥品企業、CMO的主要的收購

第6章 整體市場:競爭分析

  • 主要生物醫藥品企業和各公司的未來計劃
  • 主要企業的平台
  • 生物製藥用API的市場:產品矩陣
  • 波特的五力分析

第7章 整體市場:公司內部製造 vs 外包

  • 全球受託製造聯盟
  • 生物醫藥品產業上的最佳業務實踐
  • 總論
  • 免責聲明

第8章 附錄

  • 主要企業

第9章 關於FROST & SULLIVAN

目錄
Product Code: NE20-01-00-00-00

Redefining the Future of Biologics through Target-specific Drugs and Novel Technologies

This study provides an insight into the global biologics active pharmaceutical ingredients (API) market. According to the US FDA, “Biological products, or biologics, are medical products made from a variety of natural sources (human, animal, or microorganism). Biologics are intended to treat diseases & medical conditions and prevent or diagnose diseases.” Biologic drugs are significantly derived from monoclonal antibodies, recombinant proteins, vaccines, and others (e.g., cell therapy, gene therapy, antibody drug conjugates). In this study, drivers, restraints, and the competitive landscape as well as outsourcing and market and technology trends are discussed. Estimates and forecasts for the global market are provided from 2016 to 2020.

Table of Contents

1. EXECUTIVE SUMMARY

  • Key Findings
  • Key Findings (continued)
  • CEO's Perspective

2. TOTAL BIOLOGICS API MARKET-AN OVERVIEW

  • Market Definitions
  • Global Biologics API Market-An Overview
  • Global Biologics API Product Segmentation and Therapeutic Categories
  • Antibody and Recombinant Protein Production Process
  • Vaccines and Gene Therapy Production Process

3. TOTAL BIOLOGICS API MARKET-MARKET DRIVERS AND RESTRAINTS

  • Market Drivers
  • Drivers Explained
  • Drivers Explained (continued)
  • Drivers Explained (continued)
  • Market Restraints
  • Restraints Explained
  • Restraints Explained (continued)
  • Regulatory Landscape-Biologics

4. TOTAL BIOLOGICS API MARKET-FORECAST AND TRENDS

  • Market Engineering Measurements
  • Revenue Forecast
  • Revenue Forecast Discussion
  • Percent Revenue Breakdown by Region
  • Percent Revenue Breakdown by Biologic Drug Class

5. TOTAL BIOLOGICS API MARKET-TECHNOLOGY AND MARKET TRENDS

  • Global Trends in Biologics Market
  • Global Trends in Biologics Market (continued)
  • Global Technology Trends in Biologics
  • Global Significant Expansions by Top Biopharma Companies and CMOs
  • Global Significant Expansions by Top Biopharma Companies and CMOs (continued)
  • Global Major Acquisitions by Top Biopharma Companies and CMOs

6. TOTAL BIOLOGICS API MARKET-COMPETITIVE ANALYSIS

  • Top Biopharmaceutical Companies and Their Future Plans by 2020
  • Biologic Drug Pipeline across Therapeutic Categories and Biologic Class by Major Companies
  • Biologic Drugs Pipeline of Key Companies
  • Biologics API Market-Product Matrix
  • Biologics API Market-Product Matrix (continued)
  • Porter's Five Forces Analysis
  • Porter's Five Forces Discussion
  • Porter's Five Forces Discussion (continued)
  • Porter's Five Forces Discussion (continued)
  • Porter's Five Forces Discussion (continued)
  • Porter's Five Forces Discussion (continued)

7. TOTAL BIOLOGICS API MARKET-IN-HOUSE VS. OUTSOURCING

  • Global Contract Manufacturing Partnerships
  • Best Practices in the Biopharma Industry
  • The Last Word
  • Legal Disclaimer

8. APPENDIX

  • Major Companies

9. THE FROST & SULLIVAN STORY

  • The Frost & Sullivan Story
  • Value Proposition
  • Global Perspective
  • Industry Convergence
  • 360° Research Perspective
  • Implementation Excellence
  • Our Blue Ocean Strategy
Back to Top